More than a decade after Kymab was first backed by the Wellcome Trust to derive drug candidates from an engineered mouse model, the company has accepted a $1.1 billion takeout offer from Sanofi that closely...

The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...

Preclinical publications highlighted in BioCentury’s Distillery this year identified white space target opportunities including untapped E3 ubiquitin ligases, vesicular regulators and ion channels, as...

Phase III data from AstraZeneca and Amgen’s tezepelumab suggests the mAb could substantially expand the use of biologics in severe asthma beyond the subset of patients addressed by marketed therapies....

Kinaset is launching with a $40 million series A led by  5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in severe...

Roche’s mAb depletes regulatory T cellsRoche (SIX:ROG; OTCQX:RHHBY) and University College London scientists reported in Nature Cancer that the anti-CD25 mAb RG6292, which is in a Phase I trial in advanced...

Phase III data for coming entrants to the atopic dermatitis market show Rinvoq upadacitinib from AbbVie Inc. (NYSE:ABBV) has the edge in efficacy, compared with three other Phase III programs and the marketed therapy Dupixent...

DISEASE CATEGORY: Cancer INDICATION: Melanoma; colorectal cancer Inhibiting the glucocorticoid receptor could treat melanoma and colorectal cancer and enhance sensitivity to checkpoint blockade. In...

A growing list of cytokine therapies have been designed to boost cytotoxic immune responses against cancer while sidestepping the limitations of past candidates by controlling where the molecules do and...

Connect raises $115M C round, eyes pivotal trialsRA Capital’s Derek DiRocco will join the board of Suzhou Connect Biopharmaceuticals Ltd. after the firm led the Chinese biotech’s $115 million series C round.  Additional new investors Lilly...